Wattel A, et al
However, in the new and clarified decision (2023), the limitations for subsidization of Ozempic are as follows: Subsidized only for patients with T2DM who first tried metformin, sulphonylureas or insulin, or where these are not appropriate [48]
As discussed below, some plans with a general annual deductible for most services exclude specified classes of care from the deductible, such as prescriptions or physician office visits
1 Therefore, T2D needs progressive therapeutic intensification targeting -cells, as described in worldwide diabetes-management guidelines
Disclosed by Eli Lilly investigators in 2022 under the development code LY3437943, retatrutide builds conceptually on the dual-incretin foundation established by tirzepatide while extending receptor engagement to include the glucagon receptor, a pharmacological pathway that earlier incretin research had largely avoided due to concerns about hyperglycemia and lipolysis